However, current selective catalytic hydroxamate HDAC6inhibitors have demonstrated selectivity and toxicity liabilities.19 An alternative approach to inhibit or modulateHDAC6 function is to target protein aggregate recognition by the UBDwith small molecule antagonists, both in isolation or in combinationwith catalytic inhibition, as has been demonstrated by HDAC6 knockdownor HDAC6-degraders in the context of inflammation,20,21 infection,22−24 or proteinopathy pathologies.25 This evidence concerns the gene HDAC6 and proteostasis deficiencies.